Reduced Radiation for HPV-Positive Oropharyngeal Cancer
This study is testing if a lower dose of radiation to areas without visible cancer is as effective as the standard dose for HPV-positive oropharyngeal squamous cell carcinoma (throat cancer). You would receive standard chemotherapy with Cisplatin and a new radiation approach. The radiation will first cover the main tumor and surrounding areas, then focus only on the visible tumor. Researchers hope this approach will reduce side effects while still treating the cancer effectively. This study is for people aged 18 and older with confirmed HPV-positive oropharyngeal cancer that meets specific staging criteria. The main goal is to see how this reduced radiation dose affects progression-free survival (how long you live without the cancer getting worse) after two years. The study plans to enroll 31 participants, but its current recruitment status is unclear.
- Study design
- This is a single-arm, Phase II study, meaning all 31 participants will receive the same treatment. It is designed to investigate a reduced radiation dose.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progression-free survival will be measured at 2 years after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Change in dose and volume to all clinical target volumes (CTV) via Progression-Free Survival (PFS)2 years post treatment
To evaluate the efficacy of a reduction in dose and volume to all clinical target volumes (CTV) in patients with HPV-positive squamous cell carcinoma of the oropharynx (OPSCC) using 2-year Progression-Free Survival (PFS). Efficacy will be determined by the PFS rate at 2 years post-treatment, through continuous assessment with a boundary of 10% progression at 2 years (90% 2 year PFS).